**Name of journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 11263**

**Columns: TOPIC HIGHLIGHT**

WJG 20th Anniversary Special Issues (6): *Helicobacter pylori*

Evidence-based assessment of proton-pump inhibitors in *Helicobacter pylori* eradication: A systematic review

Nagaraja V *et al.* Proton-pump inhibitors in *Helicobacter pylori* eradication

Vinayak Nagaraja, Guy D Eslick

**Vinayak Nagaraja, Guy D Eslick**, The Whiteley-Martin Research Centre, Discipline of Surgery, The Sydney Medical School Nepean, Penrith, NSW 2751, Australia

**Author contributions:** All authors contributed to this work.

**Correspondence to: Guy D Eslick, Associate Professor,** The Whiteley-Martin Research Centre, Discipline of Surgery, The University of Sydney Nepean Hospital, Level 5, South Block, PO Box 63, Penrith, NSW 2751, Australia. guy.eslick@sydney.edu.au

**Telephone:** +61-2-47341 373 **Fax:** +61-2-47343432

**Received:** October 11, 2013 **Revised:** May 15, 2014

**Accepted:** May 23, 2014

**Published online:**

**Abstract**

Peptic ulcer disease continues to be issue especially due to its high prevalence in the developing world. *Helicobacter pylori* (*H. pylori*)infection associated duodenal ulcers should undergo eradication therapy. There are many regimens offered for *H. pylori* eradication which include triple, quadruple, or sequential therapy regimens. The central aim of this systematic review is to evaluate the evidence for *H. pylori* therapy from a meta-analytical outlook. The consequence of the dose, type of proton-pump inhibitor, and the length of the treatment will be debated. The most important risk factor for eradication failure is resistance to clarithromycin and metronidazole.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** *Helicobacter pylori*;Peptic ulcer disease; Systematic review; Proton-pump inhibitors

**Core tip:** This review will discuss the different traits of treatment regimens for *Helicobacter pylori* (*H. pylori*) and will also give an insight about some unconventional and novel treatment strategies from a meta-analytic viewpoint. This review summarizes the recommendations and level of evidence regarding the role of the dose, type of proton-pump inhibitor, and the length of the treatment. The review also discusses the various regimes for second line therapy, sequential Therapy and new alternate/adjuvant therapies for *H. pylori* therapy.

Nagaraja V, EslickGD. Evidence-based assessment of proton-pump inhibitors in *Helicobacter pylori* eradication: A systematic review. *World J Gastroenterol* 2014; In press

**INTRODUCTION**

Marshall and Warren identified and subsequently cultured the *Helicobacter pylori* (*H. pylori*) in 1982[1]. This organism is associated with chronic gastritis[2], most peptic ulcers[3], and gastric adenocarcinoma[4] and lymphoma[5]. A meta-analysis that included seven controlled trials (all in areas with a high incidence of gastric cancer) found significantly lower rates of gastric cancer (1.1% *vs* 1.7%) in patients randomized to eradication (OR = 0.65, 95%CI: 0.43-0.98)[6].

There are numerous regimens recommended for *H. pylori* eradication which include triple, quadruple, or sequential therapy regimens. Currently regimens that use proton-pump inhibitors (PPIs) in combination with several antibiotics such as clarithromycin, amoxycillin and metronidazole have been highly successful for *H. pylori* eradication[7,8]. Numerous treatments have been evaluated for *H. pylori* therapy in randomized controlled trials[9-11]. In spite of the numerous studies, the ideal schedule is still controversial. This review will discuss the different traits of treatment regimens for *H. pylori* and will also give an insight about some unconventional and novel treatment strategies from a meta-analytic viewpoint.

**LITERATURE SEARCH**

We followed the Preferred Reporting Items for Systematic reviews and Meta-Analyses PRISMA guidelines where possible in performing our systematic review[12]. We performed a systematic search through MEDLINE (from 1950), PubMed (from 1946), EMBASE (from 1949), Current Contents Connect (from 1998), Cochrane library, Google scholar, Science Direct, and Web of Science to July 2013. The search terms included “*Helicobacter pylori*, gastric cancer, intestinal metaplasia, gastric atrophy, dysplasia, prevention, treatment, and eradication. In addition, we identified relevant trials from the reference list of each selected article. Selection criteria were established. To be eligible, the studies have to be systematic reviews or meta-analyses about various eradication regimes and alternate remedies. No language restrictions were used in either the search or study selection. The reference lists of relevant articles were also searched for appropriate studies. A search for unpublished literature was not performed.

**WHAT IS THE ROLE OF THE DIFFERENT PPI DOSES IN *H. PYLORI* ERADICATION THERAPY?**

A combination of a double dose of proton pump inhibitor plus two antibiotics is the standard regimen for *Helicobacter pylori* infection. A report also suggests that the use of single dose of proton pump inhibitor is similarly efficacious[13]. Unitat de Malalties Digestives[13] conducted a MEDLINE search for their meta-analysis comparing single and double dose of a proton pump inhibitor head to head in triple therapy for *Helicobacter pylori* eradication. As a result thirteen studies were included (double dose of proton pump inhibitor: 1211 patients, single dose of proton pump inhibitor: 1180 patients). Eradication rates with double doses of proton pump inhibitor (80 mg of pantaprazole, 60 mg of lansoprazloe, 40 mg of omeprazole) were greater in both the intention-to-treat analysis and per protocol analysis. To summarize, the use of high-dose (twice a day) PPI increases the effectiveness of triple therapy compared to a single dose PPI (Level of evidence 1b, Grade of recommendation A)[14].

**DIFFERENT PPIS IN *H. PYLORI* ERADICATION THERAPY**

In a systematic review published by Gisbert *et al*[[15](#_ENREF_15)] low doses of rabeprazole (10 mg *bid*), reached similar *H. pylori* eradication rates to omeprazole and lansoprazole. (Figure 1) A systematic review regarding lansoprazole demonstrates a greater efficacy in eradicating *H. pylori*. 1076 patients were prescribed rabeprazole and 1150 with other PPIs. This efficacy is comparable to that of other PPIs[16]. Twelve studies equating pantoprazole and other PPIs were included in a meta-analysis by Gisbert *et al*[[17](#_ENREF_17)] The average *H. pylori* eradication rate for using pantoprazole plus antibiotics was similar in the two cohorts. A sub-analysis was no different statistically which included only studies comparing pantoprazole with omeprazole, or pantoprazole with lansoprazole. The subgroup analysis of six studies administering equivalent doses of all PPIs established statistically homogeneous results with pantoprazole.

Shanghai Institute of Digestive Disease[[18](#_ENREF_18)] screened 75 articles and included 11 RCTs (2,159 subjects) in their meta-analysis of esomeprazole-based triple therapy. The mean *H. pylori* eradication rates (intention-to-treat, ITT) with esomeprazole + antibiotics were 6% higher than other PPI therapies with a statistically significant odd ratio of 1.38. A subgroup analysis of six selected high-quality studies produced statistically homogeneous results. In 2004, Gisbert *et al*[[19](#_ENREF_19)] performed a similar meta-analysis and published analogous results. Vergara *et al*[[20](#_ENREF_20)] performed a MEDLINE search for their meta-analysis of fourteen studies that compared the efficacy of different proton-pump inhibitors in triple therapy showed similar results. The effectiveness of different proton-pump inhibitors is comparable in standard triple therapy.

**DURATION OF PPI-BASED TRIPLE THERAPIES**

An extended period of therapy (2 wk against 1 wk) could be more efficacious in eradicating infection but this is contentious[21,22]. Fuccio *et al*[21] performed a meta-analysis with 21 studies. Diarrhea and dysgeusia were the most commonly described side effects (5%). They concluded that prolonging the period of PPI-clarithromycin-containing triple treatment from 7 to 10–14 d increases the eradication rate by about 5%. This is currently equates to level of evidence 1b and grade of recommendation A[14].

**PPI-BASED TRIPLE REGIMENS AS OPPOSED TO QUADRUPLE THERAPY**

The University of North Texas Health Science Center performed a meta-analysis with 93 studies (10178 participants)[23]. For triple therapies, clarithromycin resistance had a larger effect on treatment effectiveness than nitroimidazole resistance. Metronidazole resistance reduced effectiveness by a quarter in triple therapies containing a nitroimidazole, tetracycline and bismuth, while effectiveness was reduced by only 14% when a proton pump inhibitor was added to the regimen. The occurrence of nitroimidazole and clarithromycin resistance has increased considerably; standard triple therapies are inadequate to eradicate *H. pylori*. Quadruple regimens are usually used as second line; they should be considered as first-line, essentially in areas of high drug resistance however, it may not be effective in context of concomitant clarithromycin and metronidazole resistance. In regions of low clarithromycin resistance, clarithromycin- containing treatments are recommended for first-line empirical treatment. However, Bismuth-containing quadruple treatment is also an alternative. (Level of evidence 1a, Grade of recommendation A)[[14](#_ENREF_14)]. In areas of high clarithromycin resistance, bismuth-containing quadruple treatments are recommended for first-line empirical treatment. If this regimen is not available a non-bismuth quadruple treatment is recommended(Level of evidence 1a, Grade of recommendation A)[[14](#_ENREF_14)].

**SEQUENTIAL THERAPY FOR *HELICOBACTER PYLORI* INFECTION**

Multiple randomized trials have demonstrated that sequential therapy and concomitant quadruple therapy are equally effective for eradication of *H. pylori* in treatment-naïve patients. Sequential therapy for 14 d may be more effective in eradicating *H. pylori* as compared with triple therapy in regions where clarithromycin resistance is high and metronidazole resistance is low[24-27]. This difference in antimicrobial resistance patterns may explain the seemingly contradictory results in two randomized controlled trials conducted in Taiwan and Latin America[28, 29]. In a randomized controlled trial in Taiwan, 900 adults with *H. pylori* were assigned to 14-day triple therapy (lansoprazole, amoxicillin, and clarithromycin) or 14-day sequential therapy (lansoprazole and amoxicillin for seven days followed by lansoprazole, clarithromycin, and metronidazole for seven days) or 10-day sequential therapy (lansoprazole and amoxicillin for five days followed by lansoprazole, clarithromycin, and metronidazole for five days)[29]. In this study, 14-day sequential therapy was significantly more likely to eradicate *H. pylori* as compared with the 14-day triple therapy. In contrast, in a randomized trial of 1463 *H. pylori* infected patients in Latin America, 14-day triple therapy (lansoprazole, amoxicillin, and clarithromycin) had higher eradication rates than five-day concomitant quadruple therapy (lansoprazole, amoxicillin, clarithromycin, and metronidazole) and 10-day clarithromycin containing sequential therapy (82, 74, and 77 percent, respectively)[28]. However, among 1091 patients in whom *H. pylori* had been successfully eradicated, one-year recurrence rates were not significantly different based on the antibiotic regimen[30].

Horvath *et al*[[31](#_ENREF_31)] ten RCTs involving a total of 857 children. This resulted in a statistically significant relative risk of 1.14 and with a number needed to treat of 15 for the eradication rate for Sequential therapy. Sequential therapy had greater efficacy to 7-day standard triple therapy, however failed to statistical significant better results than 10-day or 14-day triple therapy. The risks of adverse effects were similar in the different groups.

In 2008 University of Louisville[[32](#_ENREF_32)] concluded that sequential therapy is better than standard triple therapy for eradication of *H. pylori* infection. However, there was clear evidence of publication bias.

Gatta *et al*[[33](#_ENREF_33)] included ten RCTs with 3006 adults. The eradication rate for *H. pylori* with sequential therapy (ST) compared with triple therapy (TT) produced a number needed to treat of 6. In patients with clarithromycin resistance, eradication with ST was clearly 10 times more superior to TT. However, the number of studies was small. (Figure 3) In regions of high clarithromycin resistance, bismuth-containing quadruple treatments are suggested for first-line empirical treatment if this is unavailable, sequential treatment is the level of evidence 1a and with a grade A recommendation[14].

**PPIS AS OPPOSED TO RANITIDINE BISMUTH CITRATE-BASED REGIMENS**

Gisbert *et al*[[9](#_ENREF_9)] performed a meta-analysis using randomized controlled trials that compared PPI *vs* ranitidine bismuth citrate (RBC) plus two antibiotics for 1 wk. The mean *H. pylori* eradication with 7-day RBC-clarithromycin-amoxicillin, RBC-clarithromycin-nitroimidazole, and RBC-amoxicillin-nitroimidazole were 83%, 86%, and 71%, respectively. They concluded the effectiveness of ranitidine bismuth citrate and PPI-based triple regimens were similar. Nonetheless, equating PPI *vs* RBC plus clarithromycin and a nitroimidazole demonstrated superior cure rates with RBC than with PPI.

Two other meta-analyses published in Alimentary Pharmacology and Therapeutics by the University Medical Centre St[[34](#_ENREF_34)] and University Hospital of 'La Princesa'[[35](#_ENREF_35)] proposed similar conclusions. The effectiveness of RBC and PPI-based triple regimens are similar to the clarithromycin-amoxicillin or the amoxicillin-metronidazole combination. Nevertheless, RBC seems to have a greater effectiveness than PPI when clarithromycin and a nitroimidazole are the antibiotics administered.

***H. PYLORI* ERADICATION WHEN FIRST-LINE THERAPY FAILS: QUINOLONE-BASED RESCUE REGIMENS**

Fluoroquinolones are inhibitors of bacterial DNA synthesis by inhibiting DNA gyrase and topoisomerase IV[36]. The First Affiliated Hospital of Nanjing Medical University[37] in 2010 conducted a meta-analysis compare the efficacy and safety of clarithromycin and second-generation fluoroquinolone-based triple therapy *vs* bismuth-based quadruple therapy for the treatment of persistent *Helicobacter pylori* infection. Thirteen RCTs equated levofloxacin-based triple therapy to bismuth-based quadruple therapy; the eradication rates of the two regimens were similar. However, the eradication rates established greater efficacy for the 10-day levofloxacin-based triple therapy over 7-day bismuth-based quadruple therapy and was better accepted than bismuth-based quadruple therapy with lower incidence of adverse events and lower rates of cessation of therapy due to side effects.

Similar meta-analyses performed by University of Michigan Medical Center[[38](#_ENREF_38)] and University Hospital of 'La Princesa'[[39](#_ENREF_39)] concluded that 10-day course Quinolone triple therapy has superior efficacy than 7-day bismuth-based quadruple therapy in the treatment of stubborn *H. pylori* infection. Evidence-Based Medicine Center of Lanzhou University[[40](#_ENREF_40)] proved that Moxifloxacin-based triple therapy is superior and does not rise the frequency of adverse events equated to clarithromycin-based triple therapy. Fluoroquinolone -based triple therapy is more active and does not increase the incidence of overall side effects compared to clarithromycin-based triple therapy in the treatment of *H. pylori* infection. *H. pylori* resistant to a PPI-clarithromycin containing therapy, either a bismuth containing quadruple therapy or Levofloxacin containing triple therapy is suggested (Level of evidence 1b, Grade of recommendation A)[14]. The first-line regimens for *H. pylori* eradication have been summarized in Table 1.

**ADVERSE EFFECTS**

The incidence of side effects is up to half of the individuals taking one of the triple therapies[41,42]. These are typically minor; fewer than 10 percent of individuals halt treatment due to side effects[42].

The most common adverse effect reported due to metronidazole or clarithromycin is a metallic taste[43]. Metronidazole can lead to a disulfiram-like reaction, peripheral neuropathy, and seizures[43]. Clarithromycin can cause taste alteration, nausea, vomiting, abdominal pain, and rarely QT prolongation[43]. Doxycycline and tetracycline can lead to a photosensitivity reaction and it is contraindicated in pregnant women and young children. Amoxicillin can cause diarrhea or skin rash[43].

Levofloxacin has been linked with anorexia, nausea, vomiting, and abdominal discomfort[43]. In institutional settings with outbreaks of the epidemic fluoroquinolone-resistant strain of *Clostridium difficile* (*C. difficile*), use of fluoroquinolones has been a risk factor for development of *C. difficile*-associated diarrhea[44]. Central nervous system toxicities of levofloxacin including mild headache and dizziness have predominated, followed by insomnia and alterations in mood. Other adverse effects comprise of rashes and other allergic reactions, tendinitis and tendon rupture, QT prolongation, hypoglycemia and hyperglycemia, and hematologic toxicity[43].

Common side effects of Bismuth subcitrate are blackening of faeces, darkening of teeth and tongue. The infrequent adverse effects are nausea, vomiting, dizziness, headache and diarrhea[43].

The primary concern with bismuth compounds is bismuth intoxication; this was a problem primarily when bismuth subgallate was used for prolonged periods at high doses. Bismuth absorption varies with the specific form of bismuth; absorption is much greater with colloidal bismuth subcitrate than with bismuth subsalicylate[45]. Concurrent administration of H2 receptor antagonists increases bismuth absorption from CBS, but not from bismuth subsalicylate[46]. Nevertheless, significant clinical toxicity has not been reported in clinical trials with colloidal bismuth subcitrate or bismuth subsalicylate[47,48]. Bismuth should be avoided or serum bismuth concentrations monitored in patients with renal failure[49].

The subsalicylate moiety in bismuth subsalicylate is converted to salicylic acid and absorbed; however, salicylate in the absence of the acetyl group does not inhibit platelet function or appear to share the same high risk of aspirin for gastrointestinal bleeding[50,51]. However, the salicylate from bismuth subsalicylate will contribute to serum salicylate levels and cause salicylate toxicity, and combination with other salicylate products should therefore be avoided.

Proton pump inhibitors are usually well accepted. Common side effects include headache, nausea, vomiting, diarrhea, abdominal pain, constipation and flatulence. Uncommon adverse effects are rash, itch, dizziness, fatigue, drowsiness, insomnia and dry mouth[43]. There have been some concerns regarding long term use of proton pump inhibitors.

Recently, a meta-analysis of 42 observational studies that included 313000 patients found that PPI use was linked with an increased risk of both incident and recurrent C. difficile infection (OR = 1.7; 95%CI: 1.5-2.9 and 2.5; 95%CI: 1.2-5.4, respectively)[52]. A meta-analysis of 31 studies found that patients taking PPIs or H2 receptor antagonists were at increased risk for pneumonia, with an odds ratio of 1.27 (95%CI: 1.11-1.46) with PPIs and 1.22 (95%CI: 1.09-1.36) with H2 receptor antagonists[53]. Hypomagnesemia due to reduced intestinal absorption has been described[54]. Yu *et al*[55] included 11 studies to evaluate the relationship between proton pump inhibitor or H2 receptor antagonist use and fractures (1084560 patients with 62210 PPI users, 71339 patients with hip fractures, 161179 patients with any-site fractures, and 5728 patients with spine fractures) The risk of hip fracture was increased among PPI users compared with nonusers (RR = 1.30, 95%CI: 1.19-1.43). There was also an increased risk of spine fracture (RR = 1.56, 95%CI: 1.31-1.85) and any-site fracture (RR = 1.16, 95%CI: 1.02-1.32)[55].

**ALTERNATIVE THERAPIES**

***Probiotics***

The intestinal tract is host to a vast ecology of microbes, which are necessary for health, but also have the potential to contribute to the development of diseases by a variety of mechanisms. Perturbations in intestinal epithelial barrier function or innate immune bacterial killing, for example, can lead to an inflammatory response caused by increased uptake of bacterial and food antigens that stimulate the mucosal immune system[56,57]. The maximum understanding has been in the inflammatory bowel diseases, ulcerative colitis[58], Crohn's disease[59], and pouchitis[60-62], although clinical trials are emerging in several other conditions.

Wang *et al*[63] proposed that regular consumption of yogurt containing Lactobacillus acidophilus or Bifidobacterium lactis successfully curbed *H. pylori* infection in human beings. The Medical University of Warsaw[64] identified Five RCTs that compared with placebo or no intervention, Saccharomyces boulardii given along with triple therapy. When *S. boulardi*i was given along with triple therapy a significant increase in eradication rates was observed and lowered the rate of side effects principally of diarrhea.

The Shanghai Institute of Digestive Disease[65] performed a meta-analysis using 14 randomized trials with 1671 subjects. The pooled *H. pylori* eradication rates improved significantly with an odds ratio of 1.84 the incidence of total side effects was reduced by almost 14% and reduced diarrhea significantly. (Figure 2)

Zou *et al*[66] identified nine randomized trials (*n* = 1343) in their meta-analysis that investigated the role of lactoferrin. The pooled *H. pylori* eradication rates improved significantly with an odds ratio of 2.26 and the rate of total side-effects reduced by half, particularly nausea.

Probiotics have reduced the incidence of total side effect *H. pylori* therapy-related side effects and could be an efficacious strategy in amplifying eradication rates of anti-*H. pylori* therapy and might be useful for patients with eradication failure. (Level of evidence 5, Grade of recommendation D)[14].

***Chinese herbal therapy***

Herbs have been used conventionally for the management of a extensive variety of ailments, including gastrointestinal ailments[67]. Department of Gastroenterology at Shuguang Hospital[68] assessed the efficacy of traditional Chinese medicine by performing a systematic review with the help of sixteen trials. Large statistical heterogeneity was observed among the trials. The mean eradication rates subsequent traditional Chinese medicine and triple therapy were similar and the incidence of side effects was 15 times lower with Chinese medicine (Figure 4).

Guangzhou University of Chinese Medicine[69] reported that oral administration with HZJW and ranitidine in rodent experimental models considerably reduced the ulcerative lesion index in a dose-dependent way.

Liu *et al*[70] investigated the bactericidal effects of Jinghua Weikang Capsule and its individual herb *Chenopodium ambrosioides L.* against antibiotic-resistant *Helicobacter pylori*. In vitro they are considered to be active against antibiotic-resistant *H. pylori*.

Many Brazilian medicinal plants likeDavilla elliptica and Davilla nitida[71], Alchornea glandulosa[72], Mouririelliptica[73], Calophyllum brasiliense Camb[74-76], Hancornia speciosa[77], Strychnos species[78] and many more have been evaluated for their anti-*Helicobacter pylori* effect *in vitro*.

***Honey***

Honey is frequently utilized by numerous individuals with the trust due to its antimicrobial properties, cost effectiveness and accessibility. It is utilized as a wound antiseptic and cough syrup. University of Buea[79] assessed the antimicrobial potential of honeys (Manuka™, Capillano®, Eco- and Mountain) at diverse concentrations against of *H. pylori*, no statistically significant difference was eminent among the honeys at diverse concentrations.. The antimicrobial properties of these honeys at diverse concentrations were highly analogous to clarithromycin. A prospective randomized trial would help in deciding its efficacy.

***Green tea***

Tea extracts for instance catechins deter the growth of *Staphylococcus aureus, Staphylococcus epidermidis, Vibrio cholerae O1, V. cholerae non-O1, Vibrio parahaemolyticus, Vibrio mimicus, Campylobacter jejuni and Plesiomonas shigelloides* in vitro[80] and have antimicrobial activity against meticillin-resistant S. aureus (MRSA) in vitro[81].

University of Massachusetts Medical School[82] assessed the antimicrobial activity of green tea against Helicobacter felis and *H. pylori* in vitro and assessed the consequence of green tea on the pathogenesis of Helicobacter-induced gastritis in an animal experimental model. This resulted in significant inhibition of Helicobacter and averts gastric mucosal inflammation if consumed before being infected with Helicobacter.

Similarly an Italian study[83] proposed that in H pylori-infected mice, Ethanol-free red wine and green tea mixture considerably reduced gastritis, restricted the localization of bacteria and VacA to the gastric mucosa. Another study from Japan[84] concluded that *Helicobacter pylori* was significantly decreased by Green tea catechins-sucralfate in Mongolian gerbils.

Recently, Yonsei University[85] performed a meta-analysis regarding green tea consumption and stomach cancer risk. A total of 18 studies were incorporated in the publication which demonstrated a statistically significant of 14% reduction in the risk of stomach cancer with high green tea consumption. Some studies have suggested that Green tea has antimicrobial activity[87,87], which can extend to *Helicobacter pylori*. Natural remedies could be used in the future for inhibition and management of Helicobacter-induced gastritis in Homo sapiens however, further studies are required in this field.

**CONCLUSION**

The advancement of H pylori treatment over the years has been admirable. Bismuth-containing quadruple regimens for 7–14 d are alternative first-line treatment option. Sequential therapy for 10 days has revealed potential. Bismuth quadruple therapy is the most commonly used rescue regimen in patients with persistent *H. pylori*. The first-line regimens for *H. pylori* eradication are listed in Table 1. Current facts propose that a PPI, levofloxacin, and amoxicillin for 10 d is superior to bismuth quadruple therapy for persistent *H. pylori* infection[88]. The current literature suggests that probiotics[[64](#_ENREF_64)] and Chinese herbal therapy[68] might be beneficial in eradicating *H. pylori*. Further research in the area of alternative medicine might help us achieve higher rates of eradication and reduce side effects.

**REFERENCES**

1 **Marshall BJ**, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. *Lancet* 1984; **1**: 1311-1315 [PMID: 6145023 DOI: 10.1016/S0140-6736(84)91816-6]

2 **Dixon MF**, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. *Am J Surg Pathol* 1996; **20**: 1161-1181 [PMID: 8827022 DOI: 10.1097/00000478-199610000-00001]

3 **Ciociola AA**, McSorley DJ, Turner K, Sykes D, Palmer JB. Helicobacter pylori infection rates in duodenal ulcer patients in the United States may be lower than previously estimated. *Am J Gastroenterol* 1999; **94**: 1834-1840 [PMID: 10406244 DOI: 10.1111/j.1572-0241.1999.01214.x]

4 Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. *IARC Monogr Eval Carcinog Risks Hum* 1994; **61**: 1-241 [PMID: 7715068]

5 **Zucca E**, Bertoni F, Roggero E, Bosshard G, Cazzaniga G, Pedrinis E, Biondi A, Cavalli F. Molecular analysis of the progression from Helicobacter pylori-associated chronic gastritis to mucosa-associated lymphoid-tissue lymphoma of the stomach. *N Engl J Med* 1998; **338**: 804-810 [PMID: 9504941 DOI: 10.1056/NEJM199803193381205]

6 **Fuccio L**, Zagari RM, Eusebi LH, Laterza L, Cennamo V, Ceroni L, Grilli D, Bazzoli F. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? *Ann Intern Med* 2009; **151**: 121-128 [PMID: 19620164 DOI: 10.7326/0003-4819-151-2-200907210-00009]

7 **Gisbert JP**, González L, Calvet X, García N, López T, Roqué M, Gabriel R, Pajares JM. Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. *Aliment Pharmacol Ther* 2000; **14**: 1319-1328 [PMID: 11012477 DOI: 10.1046/j.1365-2036.2000.00844.x]

8 **Laine L**, Fennerty MB, Osato M, Sugg J, Suchower L, Probst P, Levine JG. Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. *Am J Gastroenterol* 2000; **95**: 3393-3398 [PMID: 11151867 DOI: 10.1111/j.1572-0241.2000.03349.x]

9 **Gisbert JP**, Gonzalez L, Calvet X. Systematic review and meta-analysis: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics in Helicobacter pylori eradication. *Helicobacter* 2005; **10**: 157-171 [PMID: 15904473 DOI: 10.1111/j.1523-5378.2005.00307.x]

10 **Qasim A**, Sebastian S, Thornton O, Dobson M, McLoughlin R, Buckley M, O'Connor H, O'Morain C. Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients. *Aliment Pharmacol Ther* 2005; **21**: 91-96 [PMID: 15644050 DOI: 10.1111/j.1365-2036.2004.02210.x]

11 **Gatta L**, Zullo A, Perna F, Ricci C, De Francesco V, Tampieri A, Bernabucci V, Cavina M, Hassan C, Ierardi E, Morini S, Vaira D. A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. *Aliment Pharmacol Ther* 2005; **22**: 45-49 [PMID: 15963079 DOI: 10.1111/j.1365-2036.2005.02522.x]

12 **Moher D**, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *J Clin Epidemiol* 2009; **62**: 1006-1012 [PMID: 19631508 DOI: 10.1016/j.jclinepi.2009.06.005]

13 **Vallve M**, Vergara M, Gisbert JP, Calvet X. Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. *Aliment Pharmacol Ther* 2002; **16**: 1149-1156 [PMID: 12030958 DOI: 10.1046/j.1365-2036.2002.01270.x]

14 **Malfertheiner P**, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. *Gut* 2012; **61**: 646-664 [PMID: 22491499 DOI: 10.1136/gutjnl-2012-302084]

15 **Gisbert JP**, Khorrami S, Calvet X, Pajares JM. Systematic review: Rabeprazole-based therapies in Helicobacter pylori eradication. *Aliment Pharmacol Ther* 2003; **17**: 751-764 [PMID: 12641497 DOI: 10.1046/j.1365-2036.2003.01450.x]

16 **Bazzoli F**, Pozzato P, Zagari M, Fossi S, Ricciardiello L, Nicolini G, Berretti D, De Luca L. Efficacy of lansoprazole in eradicating Helicobacter pylori: a meta-analysis. *Helicobacter* 1998; **3**: 195-201 [PMID: 9731991 DOI: 10.1046/j.1523-5378.1998.08029.x]

17 **Gisbert JP**, Khorrami S, Calvet X, Pajares JM. Pantoprazole based therapies in Helicobacter pylori eradication: a systematic review and meta-analysis. *Eur J Gastroenterol Hepatol* 2004; **16**: 89-99 [PMID: 15095858 DOI: 10.1097/00042737-200401000-00014]

18 **Wang X**, Fang JY, Lu R, Sun DF. A meta-analysis: comparison of esomeprazole and other proton pump inhibitors in eradicating Helicobacter pylori. *Digestion* 2006; **73**: 178-186 [PMID: 16837803 DOI: 10.1159/000094526]

19 **Gisbert JP**, Pajares JM. Esomeprazole-based therapy in Helicobacter pylori eradication: a meta-analysis. *Dig Liver Dis* 2004; **36**: 253-259 [PMID: 15115337 DOI: 10.1016/j.dld.2003.12.010]

20 **Vergara M**, Vallve M, Gisbert JP, Calvet X. Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication. *Aliment Pharmacol Ther* 2003; **18**: 647-654 [PMID: 12969092 DOI: 10.1046/j.1365-2036.2003.01746.x]

21 **Fuccio L**, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. *Ann Intern Med* 2007; **147**: 553-562 [PMID: 17938394 DOI: 10.7326/0003-4819-147-8-200710160-00008]

22 **Vakil N**, Connor J. Helicobacter pylori eradication: equivalence trials and the optimal duration of therapy. *Am J Gastroenterol* 2005; **100**: 1702-1703 [PMID: 16144122 DOI: 10.1111/j.1572-0241.2005.50615.x]

23 **Fischbach L**, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. *Aliment Pharmacol Ther* 2007; **26**: 343-357 [PMID: 17635369 DOI: 10.1111/j.1365-2036.2007.03386.x]

24 **Moayyedi P**, Malfertheiner P. Editorial: Sequential therapy for eradication of Helicobacter pylori: a new guiding light or a false dawn? *Am J Gastroenterol* 2009; **104**: 3081-3083 [PMID: 19956122 DOI: 10.1038/ajg.2009.563]

25 **Zullo A**, De Francesco V, Hassan C, Morini S, Vaira D. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. *Gut* 2007; **56**: 1353-1357 [PMID: 17566020 DOI: 10.1136/gut.2007.125658]

26 **Vaira D**, Zullo A, Vakil N, Gatta L, Ricci C, Perna F, Hassan C, Bernabucci V, Tampieri A, Morini S. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. *Ann Intern Med* 2007; **146**: 556-563 [PMID: 17438314 DOI: 10.7326/0003-4819-146-8-200704170-00006]

27 **Kim YS**, Kim SJ, Yoon JH, Suk KT, Kim JB, Kim DJ, Kim DY, Min HJ, Park SH, Shin WG, Kim KH, Kim HY, Baik GH. Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea. *Aliment Pharmacol Ther* 2011; **34**: 1098-1105 [PMID: 21923713 DOI: 10.1111/j.1365-2036.2011.04843.x]

28 **Greenberg ER**, Anderson GL, Morgan DR, Torres J, Chey WD, Bravo LE, Dominguez RL, Ferreccio C, Herrero R, Lazcano-Ponce EC, Meza-Montenegro MM, Peña R, Peña EM, Salazar-Martínez E, Correa P, Martínez ME, Valdivieso M, Goodman GE, Crowley JJ, Baker LH. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. *Lancet* 2011; **378**: 507-514 [PMID: 21777974 DOI: 10.1016/S0140-6736(11)60825-8]

29 **Liou JM**, Chen CC, Chen MJ, Chen CC, Chang CY, Fang YJ, Lee JY, Hsu SJ, Luo JC, Chang WH, Hsu YC, Tseng CH, Tseng PH, Wang HP, Yang UC, Shun CT, Lin JT, Lee YC, Wu MS. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. *Lancet* 2013; **381**: 205-213 [PMID: 23158886 DOI: 10.1016/S0140-6736(12)61579-7]

30 **Morgan DR**, Torres J, Sexton R, Herrero R, Salazar-Martínez E, Greenberg ER, Bravo LE, Dominguez RL, Ferreccio C, Lazcano-Ponce EC, Meza-Montenegro MM, Peña EM, Peña R, Correa P, Martínez ME, Chey WD, Valdivieso M, Anderson GL, Goodman GE, Crowley JJ, Baker LH. Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities. *JAMA* 2013; **309**: 578-586 [PMID: 23403682 DOI: 10.1001/jama.2013.311]

31 **Horvath A**, Dziechciarz P, Szajewska H. Meta-analysis: sequential therapy for Helicobacter pylori eradication in children. *Aliment Pharmacol Ther* 2012; **36**: 534-541 [PMID: 22827718 DOI: 10.1111/j.1365-2036.2012.05229.x]

32 **Jafri NS**, Hornung CA, Howden CW. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. *Ann Intern Med* 2008; **148**: 923-931 [PMID: 18490667 DOI: 10.7326/0003-4819-148-12-200806170-00226]

33 **Gatta L**, Vakil N, Leandro G, Di Mario F, Vaira D. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. *Am J Gastroenterol* 2009; **104**: 3069-379; quiz 1080 [PMID: 19844205 DOI: 10.1038/ajg.2009.555]

34 **Janssen MJ**, Van Oijen AH, Verbeek AL, Jansen JB, De Boer WA. A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole. *Aliment Pharmacol Ther* 2001; **15**: 613-624 [PMID: 11328254 DOI: 10.1046/j.1365-2036.2001.00974.x]

35 **Gisbert JP**, González L, Calvet X, Roqué M, Gabriel R, Pajares JM. Helicobacter pylori eradication: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics for 1 week-a meta-analysis of efficacy. *Aliment Pharmacol Ther* 2000; **14**: 1141-1150 [PMID: 10971230 DOI: 10.1046/j.1365-2036.2000.00809.x]

36 **Drlica K**, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. *Microbiol Mol Biol Rev* 1997; **61**: 377-392 [PMID: 9293187]

37 **Li Y**, Huang X, Yao L, Shi R, Zhang G. Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis. *Wien Klin Wochenschr* 2010; **122**: 413-422 [PMID: 20628905 DOI: 10.1007/s00508-010-1404-3]

38 **Saad RJ**, Schoenfeld P, Kim HM, Chey WD. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. *Am J Gastroenterol* 2006; **101**: 488-496 [PMID: 16542284 DOI: 10.1111/j.1572-0241.2006.00637.x]

39 **Gisbert JP**, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. *Aliment Pharmacol Ther* 2006; **23**: 35-44 [PMID: 16393278 DOI: 10.1111/j.1365-2036.2006.02737.x]

40 **Wenzhen Y**, Kehu Y, Bin M, Yumin L, Quanlin G, Donghai W, Lijuan Y. Moxifloxacin-based triple therapy versus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection: a meta-analysis of randomized controlled trials. *Intern Med* 2009; **48**: 2069-2076 [PMID: 20009394 DOI: 10.2169/internalmedicine.48.2344]

41 **Fischbach LA**, van Zanten S, Dickason J. Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. *Aliment Pharmacol Ther* 2004; **20**: 1071-1082 [PMID: 15569109 DOI: 10.1111/j.1365-2036.2004.02248.x]

42 **de Boer WA**, Tytgat GN. The best therapy for Helicobacter pylori infection: should efficacy or side-effect profile determine our choice? *Scand J Gastroenterol* 1995; **30**: 401-407 [PMID: 7638563 DOI: 10.3109/00365529509093298]

43 . (2013) Australian Medicines Handbook Adelaide: Australian Medicines Handbook

44 **McCusker ME**, Harris AD, Perencevich E, Roghmann MC. Fluoroquinolone use and Clostridium difficile-associated diarrhea. *Emerg Infect Dis* 2003; **9**: 730-733 [PMID: 12781017 DOI: 10.3201/eid0906.020385]

45 **Nwokolo CU**, Gavey CJ, Smith JT, Pounder RE. The absorption of bismuth from oral doses of tripotassium dicitrato bismuthate. *Aliment Pharmacol Ther* 1989; **3**: 29-39 [PMID: 2491456 DOI: 10.1111/j.1365-2036.1989.tb00188.x]

46 **Nwokolo CU**, Prewett EJ, Sawyerr AM, Hudson M, Pounder RE. The effect of histamine H2-receptor blockade on bismuth absorption from three ulcer-healing compounds. *Gastroenterology* 1991; **101**: 889-894 [PMID: 1889712]

47 **Wagstaff AJ**, Benfield P, Monk JP. Colloidal bismuth subcitrate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease. *Drugs* 1988; **36**: 132-157 [PMID: 3053124 DOI: 10.2165/00003495-198836020-00002]

48 **Gorbach SL**. Bismuth therapy in gastrointestinal diseases. *Gastroenterology* 1990; **99**: 863-875 [PMID: 2199292]

49 **Gladziwa U**, Koltz U. Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure. *Clin Pharmacokinet* 1994; **27**: 393-408 [PMID: 7851056 DOI: 10.2165/00003088-199427050-00006]

50 **Danesh BJ**, McLaren M, Russell RI, Lowe GD, Forbes CD. Comparison of the effect of aspirin and choline magnesium trisalicylate on thromboxane biosynthesis in human platelets: role of the acetyl moiety. *Haemostasis* 1989; **19**: 169-173 [PMID: 2744633]

51 . Sweeney JD, Hoernig LA (1991) Hemostatic effects of salsalate in normal subjects and patients with hemophilia A. Thrombosis research 61, 23-27. doi: 10.1016/0049-3848(91)90165-S

52 **Kwok CS**, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. *Am J Gastroenterol* 2012; **107**: 1011-1019 [PMID: 22525304 DOI: 10.1038/ajg.2012.108]

53 **Eom CS**, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. *CMAJ* 2011; **183**: 310-319 [PMID: 21173070]

54 **Hess MW**, Hoenderop JG, Bindels RJ, Drenth JP. Systematic review: hypomagnesaemia induced by proton pump inhibition. *Aliment Pharmacol Ther* 2012; **36**: 405-413 [PMID: 22762246 DOI: 10.1111/j.1365-2036.2012.05201.x]

55 **Yu EW**, Bauer SR, Bain PA, Bauer DC. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. *Am J Med* 2011; **124**: 519-526 [PMID: 21605729 DOI: 10.1016/j.amjmed.2011.01.007]

56 **Packey CD**, Sartor RB. Commensal bacteria, traditional and opportunistic pathogens, dysbiosis and bacterial killing in inflammatory bowel diseases. *Curr Opin Infect Dis* 2009; **22**: 292-301 [PMID: 19352175 DOI: 10.1097/QCO.0b013e32832a8a5d]

57 **Sartor RB**. Microbial influences in inflammatory bowel diseases. *Gastroenterology* 2008; **134**: 577-594 [PMID: 18242222 DOI: 10.1053/j.gastro.2007.11.059]

58 **Naidoo K**, Gordon M, Fagbemi AO, Thomas AG, Akobeng AK. Probiotics for maintenance of remission in ulcerative colitis. *Cochrane Database Syst Rev* 2011; : CD007443 [PMID: 22161412]

59 **Steed H**, Macfarlane GT, Blackett KL, Bahrami B, Reynolds N, Walsh SV, Cummings JH, Macfarlane S. Clinical trial: the microbiological and immunological effects of synbiotic consumption - a randomized double-blind placebo-controlled study in active Crohn's disease. *Aliment Pharmacol Ther* 2010; **32**: 872-883 [PMID: 20735782 DOI: 10.1111/j.1365-2036.2010.04417.x]

60 **Gionchetti P**, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, Vitali B, Poggioli G, Miglioli M, Campieri M. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. *Gastroenterology* 2003; **124**: 1202-1209 [PMID: 12730861 DOI: 10.1016/S0016-5085(03)00171-9]

61 **Gionchetti P**, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, Poggioli G, Miglioli M, Campieri M. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. *Gastroenterology* 2000; **119**: 305-309 [PMID: 10930365 DOI: 10.1053/gast.2000.9370]

62 **Mimura T**, Rizzello F, Helwig U, Poggioli G, Schreiber S, Talbot IC, Nicholls RJ, Gionchetti P, Campieri M, Kamm MA. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. *Gut* 2004; **53**: 108-114 [PMID: 14684584 DOI: 10.1136/gut.53.1.108]

63 **Wang KY**, Li SN, Liu CS, Perng DS, Su YC, Wu DC, Jan CM, Lai CH, Wang TN, Wang WM. Effects of ingesting Lactobacillus- and Bifidobacterium-containing yogurt in subjects with colonized Helicobacter pylori. *Am J Clin Nutr* 2004; **80**: 737-741 [PMID: 15321816]

64 **Szajewska H**, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. *Aliment Pharmacol Ther* 2010; **32**: 1069-1079 [PMID: 21039671 DOI: 10.1111/j.1365-2036.2010.04457.x]

65 **Tong JL**, Ran ZH, Shen J, Zhang CX, Xiao SD. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. *Aliment Pharmacol Ther* 2007; **25**: 155-168 [PMID: 17229240 DOI: 10.1111/j.1365-2036.2006.03179.x]

66 **Zou J**, Dong J, Yu XF. Meta-analysis: the effect of supplementation with lactoferrin on eradication rates and adverse events during Helicobacter pylori eradication therapy. *Helicobacter* 2009; **14**: 119-127 [PMID: 19298339 DOI: 10.1111/j.1523-5378.2009.00666.x]

67 **Borrelli F**, Izzo AA. The plant kingdom as a source of anti-ulcer remedies. *Phytother Res* 2000; **14**: 581-591 [PMID: 11113992]

68 **Lin J**, Huang WW. A systematic review of treating Helicobacter pylori infection with Traditional Chinese Medicine. *World J Gastroenterol* 2009; **15**: 4715-4719 [PMID: 19787835 DOI: 10.3748/wjg.15.4715]

69 **Xie JH**, Chen YL, Wu QH, Wu J, Su JY, Cao HY, Li YC, Li YS, Liao JB, Lai XP, Huang P, Su ZR. Gastroprotective and anti-Helicobacter pylori potential of herbal formula HZJW: safety and efficacy assessment. *BMC Complement Altern Med* 2013; **13**: 119 [PMID: 23721522 DOI: 10.1186/1472-6882-13-119]

70 **Liu W**, Liu Y, Zhang XZ, Li N, Cheng H. In vitro bactericidal activity of Jinghua Weikang Capsule and its individual herb Chenopodium ambrosioides L. against antibiotic-resistant Helicobacter pylori. *Chin J Integr Med* 2013; **19**: 54-57 [PMID: 23275015 DOI: 10.1007/s11655-012-1248-y]

Is Analyse...

72 **Calvo TR**, Lima ZP, Silva JS, Ballesteros KV, Pellizzon CH, Hiruma-Lima CA, Tamashiro J, Brito AR, Takahira RK, Vilegas W. Constituents and antiulcer effect of Alchornea glandulosa: activation of cell proliferation in gastric mucosa during the healing process. *Biol Pharm Bull* 2007; **30**: 451-459 [PMID: 17329837 DOI: 10.1248/bpb.30.451]

73 **Moleiro FC**, Andreo MA, Santos Rde C, Moraes Tde M, Rodrigues CM, Carli CB, Lopes FC, Pellizzon CH, Carlos IZ, Bauab TM, Vilegas W, Hiruma-Lima CA. Mouririelliptica: validation of gastroprotective, healing and anti-Helicobacter pylori effects. *J Ethnopharmacol* 2009; **123**: 359-368 [PMID: 19501267 DOI: 10.1016/j.jep.2009.03.040]

74 **Lemos LM**, Martins TB, Tanajura GH, Gazoni VF, Bonaldo J, Strada CL, Silva MG, Dall'oglio EL, de Sousa Júnior PT, Martins DT. Evaluation of antiulcer activity of chromanone fraction from Calophyllum brasiliesnse Camb. *J Ethnopharmacol* 2012; **141**: 432-439 [PMID: 22425905 DOI: 10.1016/j.jep.2012.03.006]

75 **Sartori NT**, Canepelle D, de Sousa PT, Martins DT. Gastroprotective effect from Calophyllum brasiliense Camb. bark on experimental gastric lesions in rats and mice. *J Ethnopharmacol* 1999; **67**: 149-156 [PMID: 10619378 DOI: 10.1016/S0378-8741(98)00244-X]

76 **Souza Mdo C**, Beserra AM, Martins DC, Real VV, Santos RA, Rao VS, Silva RM, Martins DT. In vitro and in vivo anti-Helicobacter pylori activity of Calophyllum brasiliense Camb. *J Ethnopharmacol* 2009; **123**: 452-458 [PMID: 19501278 DOI: 10.1016/j.jep.2009.03.030]

77 **Moraes Tde M**, Rodrigues CM, Kushima H, Bauab TM, Villegas W, Pellizzon CH, Brito AR, Hiruma-Lima CA. Hancornia speciosa: indications of gastroprotective, healing and anti-Helicobacter pylori actions. *J Ethnopharmacol* 2008; **120**: 161-168 [PMID: 18761076 DOI: 10.1016/j.jep.2008.08.001]

78 **Bonamin F**, Moraes TM, Kushima H, Silva MA, Rozza AL, Pellizzon CH, Bauab TM, Rocha LR, Vilegas W, Hiruma-Lima CA. Can a Strychnos species be used as antiulcer agent? Ulcer healing action from alkaloid fraction of Strychnos pseudoquina St. Hil. (Loganiaceae). *J Ethnopharmacol* 2011; **138**: 47-52 [PMID: 21959182 DOI: 10.1016/j.jep.2011.08.020]

79 **Ndip RN**, Malange Takang AE, Echakachi CM, Malongue A, Akoachere JF, Ndip LM, Luma HN. In-vitro antimicrobial activity of selected honeys on clinical isolates of Helicobacter pylori. *Afr Health Sci* 2007; **7**: 228-232 [PMID: 21499488]

80 **Toda M**, Okubo S, Ohnishi R, Shimamura T. [Antibacterial and bactericidal activities of Japanese green tea]. *Nihon Saikingaku Zasshi* 1989; **44**: 669-672 [PMID: 2677434 DOI: 10.3412/jsb.44.669]

81 **Toda M**, Okubo S, Hara Y, Shimamura T. [Antibacterial and bactericidal activities of tea extracts and catechins against methicillin resistant Staphylococcus aureus]. *Nihon Saikingaku Zasshi* 1991; **46**: 839-845 [PMID: 1762174 DOI: 10.3412/jsb.46.839]

82 **Stoicov C**, Saffari R, Houghton J. Green tea inhibits Helicobacter growth in vivo and in vitro. *Int J Antimicrob Agents* 2009; **33**: 473-478 [PMID: 19157800 DOI: 10.1016/j.ijantimicag.2008.10.032]

83 **Ruggiero P**, Rossi G, Tombola F, Pancotto L, Lauretti L, Del Giudice G, Zoratti M. Red wine and green tea reduce H pylori- or VacA-induced gastritis in a mouse model. *World J Gastroenterol* 2007; **13**: 349-354 [PMID: 17230601 DOI: 10.3748/wjg.v13.i3.349]

84 **Takabayashi F**, Harada N, Yamada M, Murohisa B, Oguni I. Inhibitory effect of green tea catechins in combination with sucralfate on Helicobacter pylori infection in Mongolian gerbils. *J Gastroenterol* 2004; **39**: 61-63 [PMID: 14767736 DOI: 10.1007/s00535-003-1246-0]


85 **Kang H**, Rha SY, Oh KW, Nam CM. Green tea consumption and stomach cancer risk: a meta-analysis. *Epidemiol Health* 2010; **32**: e2010001 [PMID: 21191454]

86 **Yam TS**, Shah S, Hamilton-Miller JM. Microbiological activity of whole and fractionated crude extracts of tea (Camellia sinensis), and of tea components. *FEMS Microbiol Lett* 1997; **152**: 169-174 [PMID: 9228784 DOI: 10.1111/j.1574-6968.1997.tb10424.x]


87 **Horiba N**, Maekawa Y, Ito M, Matsumoto T, Nakamura H. A pilot study of Japanese green tea as a medicament: antibacterial and bactericidal effects. *J Endod* 1991; **17**: 122-124 [PMID: 1940726 DOI: 10.1016/S0099-2399(06)81743-7]

88 **Chey WD**, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. *Am J Gastroenterol* 2007; **102**: 1808-1825 [PMID: 17608775 DOI: 10.1111/j.1572-0241.2007.01393.x]


**P-Reviewers:** Alsolaiman MM, Figura N, Sugimoto M, Vyas D **S-Editor:** Wen LL  **L-Editor:**  **E-Editor:**




**Figure 1 Meta-analysis of studies comparing *Helicobacter pylori* eradication with rabeprazole 10 mg *bid* *vs* omeprazole 20 mg *bid* or lansoprazole 30 mg *bid* in triple therapies[15]**. PPI: Proton pump inhibitor.



**Figure 2 The effect of probiotics supplementation *vs* without probiotics on eradication rates by intention-to-treat analysis[65].** (n: Number of successful eradication; N: Number of participants).

****

**Figure 3 Sequential *vs* triple therapy lasting 7 d[33].**



**Figure 4 Clinical trials treating *Helicobacter pylori* with traditional Chinese medicine[68]**.

**Table 1 First-line regimens for *Helicobacter pylori* eradication[88]**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Regimen | Standard dose PPI *bid* (esomeprazole is *qid*), clarithromycin 500 mg *bid*, amoxicillin 1000 mg *bid* for 10–14 d | Standard dose PPI *bid*, clarithromycin 500 mg *bid* metronidazole 500 mg *bid* for 10–14 d | Bismuth subsalicylate 525 mg *po* *qid* metronidazole 250 mg *po* *qid*, tetracycline 500 mg *po* *qid*, ranitidine 150 mg *po* *bid* or standard dose PPI *qid* to *bid* for 10–14 d | PPI + amoxicillin 1 g *bid* 5 d followed by PPI, clarithromycin 500 mg, tinidazole 500 mg *bid* for 5 d |
| Note | Consider in nonpenicillin allergic patients who have not previously received a macrolide | Consider in penicillin allergic patients who have not previously received a macrolide or are unable to tolerate bismuth quadruple therapy | Consider in penicillin allergic patients | Requires validation in North America |

PPI: Proton-pump inhibitors.